Photo from wikipedia
The National Institute for Health and Care Excellence (NICE) said in draft guidance that it cannot recommend the advanced breast cancer drug trastuzumab emtansine (Kadcyla) for routine NHS use in… Click to show full abstract
The National Institute for Health and Care Excellence (NICE) said in draft guidance that it cannot recommend the advanced breast cancer drug trastuzumab emtansine (Kadcyla) for routine NHS use in England and Wales because it is too expensive. Kadcyla, currently funded through the Cancer Drugs Fund, has been shown to extend life by as much as nine months but costs around £90 000 (€106 000; $110 500) a patient. The patient access scheme offered by the manufacturer, Roche, would have involved the NHS paying the list price for the first 14 months, after which Roche would rebate the cost of any subsequent treatment.
Journal Title: British Medical Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!